Figure 5 — Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK

Research Paper|Volume 13, Issue 17|pp. 21102–21121

Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK

Back to articleFigure 5(5 of 8)

100%

Figure 5.The ITK expression is regulated by BGB-3111 and ibrutinib in the Jurkat T-cells. (A) The ITK expression in the Jurkat T-cells treated with BGB-3111 and ibrutinib at the same dose of 2 μM for 0–48 h. (B) The percentage of inhibition rate of the ITK protein in the Jurkat T-cells treated with BGB-3111 and ibrutinib. ^**p < 0.01.